

NEWS RELEASE



MEMBERSHIP

September 29, 2025

Company Name: **Veritas In Silico Inc.**
Representative: Shingo NAKAMURA,

Representative Director and CEO

Listed on: TSE Growth

Stock Ticker Code: 130A

Contact Person: Tsuneo GODA,

Executive Officer, General Manager,

Corporate Planning Division

Email: ir@veritasinsilico.com

Relocation of the Shin-Kawasaki Research Institute

Veritas In Silico Inc. (Headquarters: Shinagawa-ku, Tokyo; Representative: Shingo Nakamura, Representative Director and CEO, hereinafter referred to as "the Company") announce that the Company has decided to relocate the Shin-Kawasaki Research Institute (hereinafter referred to as "the Relocation") as detailed below.

● Purpose of the Relocation

The research projects undertaken by the Company are becoming increasingly sophisticated year after year. The number of joint drug discovery projects and in-house pipeline development initiatives are also growing annually. The company is strengthening its research infrastructure with an eye toward the future, including expanding its AI capabilities, increasing the number of researchers, and updating research equipment. In addition to these efforts, the Company is also in the process of expanding our research facilities.

● Name and current location of Research Institute scheduled for the Relocation

Shin-Kawasaki Research Institute

7-7 Shin-Kawasaki, Saiwai-Ku, Kawasaki City, Kanagawa Prefecture

Institute of Industrial Promotion, Kawasaki City, Kawasaki Business Incubation Center

● Scheduled Destination of the Relocation

66-2 Horikawa-cho, Saiwai-Ku, Kawasaki City, Kanagawa Prefecture

KOWA KAWASAKI. NISHIGUCHI BUILDING

● Scheduled Date of the Relocation

In Mid-March 2026

● Projections of the Impact on Future Financial Condition and Business Performance

The costs of the Relocation incurred during the fiscal year ending December 2025 are already incorporated into the earnings forecast announced on February 13, 2025. There is No changes to the earnings forecast.

Upon commencement of operations at the relocated research institute in the fiscal year ending December 2026, new equipment and fixtures of the Research Institute are scheduled to be accounted for as tangible fixed assets, and depreciation shall be started. The Company anticipates that the increase in these assets and the occurrence of various expenses shall not have a significant impact on its future financial position and business results.

In case any matters requiring disclosure arise in the future, they will be promptly disclosed.

For Further Information, Contact:

- Veritas In Silico Website Inquiry Form : <https://www.veritasinsilico.com/en/contact/>